NCT03750643

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	LY3454738	Administered IV
DRUG	LY3454738	Administered SC
DRUG	Placebo	Administered IV

Timeline

• Start date: 2018-11-29
• Primary completion: 2021-09-07
• Completion: 2021-09-07
• First posted: 2018-11-23
• Last updated: 2021-10-06

Locations

21 sites across 2 countries: United States, Puerto Rico

Regulatory

• FDA-regulated drug study